Pharma reputation slips among patient advocacy groups, according to annual survey

Patient advocacy groups’ perception of pharma companies fell for the first time since beginning a steady rise five years ago, a sign that the industry may not be able to fully hang on to the improved reputation it’s enjoyed over the last several years, according to a new survey.

The survey from PatientView assessed patient groups’ opinions across 10 different issues, including integrity, transparency, equitable access, patient centricity and high-quality products, and assigned a percentage score.

Pharma’s score on the survey hit a recent high last year of 60%, and fell to 57% this year. It’s an indication that “pharma’s elevated reputational status may not be sustainable,” PatientView said in the latest edition of the annual report published Monday. In 2018, the industry had a score of 41%, which rose to 50% during the first year of the Covid-19 pandemic.

The decline from Covid-era highs isn’t…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks